Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study

Abstract

Background Treatment for infection with hepatitis C virus (HCV) during pregnancy has not yet been approved; however, interventions specifically targeting women, especially those of childbearing age (15-49 years), could prevent vertical transmission and community spread. To assess the impact of such interventions, improved prevalence estimates in this group are needed. We aimed to estimate the global prevalence of viraemic HCV in 2019 among women of childbearing age.Methods In this modelling study, we used previously developed models for 110 countries inputted with countryspecific demographic and HCV epidemiology data. We did a literature review, searching PubMed, Embase, and grey literature for studies published between Jan 1, 2000, and June 30, 2018, reporting HCV antibody or viraemic prevalence in women of childbearing age. Studies from the literature review and studies in models were compared by use of a data quality scoring system and models were updated, as appropriate, when a better study was identified. We used these HCV disease burden models to calculate the 2019 prevalence of viraemic HCV in women of childbearing age. In countries without a model, prevalence was extrapolated by Global Burden of Disease (GBD) region.Findings An estimated 14 860 000 (95% uncertainty interval [UI] 9 667 000-18 282 000) women aged 15-49 years had HCV infection worldwide in 2019, corresponding to a viraemic prevalence of 0•78% (95% UI 0•62-0•86). Globally, HCV prevalence increased with age, rising from 0•25% (95% UI 0•20-0•27) in women aged 15-19 years to 1•21% (0•97-1•34) in women aged 45-49 years. China (16% of total infections) and Pakistan (15%) had the greatest numbers of viraemic infections, but viraemic prevalence was highest in Mongolia (5•14%, 95% CI 3•46-6•28) and Burundi (4•91%, 3•80-18•75). Of the countries with 500 cases or more, viraemic prevalence was lowest in Chile (0•07%, 95% UI 0•04-0•12). Among the GBD regions, eastern Europe had the highest viraemic prevalence (3•39%, 95% UI 1•88-3•54). By WHO region, the Eastern Mediterranean region had the highest viraemic prevalence (1•75%, 95% UI 1•26-1•90).Interpretation Most research on HCV disease burden among women aged 15-49 years focuses on pregnant women. Using modelling, this analysis provides global and national estimates of HCV prevalence in all women of childbearing age. These data can inform preconception test-and-treat strategies to reduce vertical transmission and total disease burden.Funding Gilead Sciences, John C Martin Foundation, private donors.

Trends in the disease burden of HBV and HCV infection in China from 1990-2019

“…After controlling period and cohort effects, we observed that the risk of HCV-associated mortality increased with age, whereas the risk of incidence was similar across different age groups, except for those patients aged ≤5 years. The high incidences of HCV in patients aged ≤5 years might be associated with mother-to-child transmission ( Dugan et al, 2021 ;Gentile et al, 2014 ).…”

Routine screening for hepatitis C in pregnancy is cost‐effective in a large urban population in Ireland: a retrospective study

“…25 It has been estimated that the global prevalence of hepatitis C viraemia in females of child-bearing age is 0.78%. 26 This suggests these guidelines could be widely applicable, though local assessment of cost-benefit would be required.…”

Polaris Observatory—supporting informed decision-making at the national, regional, and global levels to eliminate viral hepatitis

“…The annual updates allowed us to provide up-to-date global and regional data to national agencies to notify travelers of endemic countries [18], and national blood banks of the likelihood of HCV and HBV infection among blood collected among migrants. The analyses conducted by Polaris enabled us to estimate the global prevalence of HBV and HCV in the pediatric population and women of childbearing age to support programs targeting a reduction in mother to child transmission [19][20][21].…”